Youssef Irini, Mohamed Nader, Kallini Daniel, Zakeri Kaveh, Lin Haibo, Han Dong, Qi Hang, Nosov Anton, Riaz Nadeem, Chen Linda, Yu Yao, Dunn Lara Ann, Sherman Eric J, Wray Rick, Schöder Heiko, Lee Nancy Y
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; New York Proton Center, New York, New York.
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1326-1331. doi: 10.1016/j.ijrobp.2024.03.011. Epub 2024 Mar 16.
One main advantage of proton therapy versus photon therapy is its precise radiation delivery to targets without exit dose, resulting in lower dose to surrounding healthy tissues. This is critical, given the proximity of head and neck tumors to normal structures. However, proton planning requires careful consideration of factors, including air-tissue interface, anatomic uncertainties, surgical artifacts, weight fluctuations, rapid tumor response, and daily variations in setup and anatomy, as these heterogeneities can lead to inaccuracies in targeting and creating unwarranted hotspots to a greater extent than photon radiation. In addition, the elevated relative biological effectiveness at the Bragg peak's distal end can also increase hot spots within and outside the target area.
The purpose of this study was to evaluate for a difference in positron emission tomography (PET) standard uptake value (SUV) after definitive treatment, between intensity modulated proton therapy (IMPT) and intensity modulated photon therapy (IMRT). In addition, we compared the biologic dose between PET areas of high and low uptake within the clinical target volume-primary of patients treated with IMPT. This work is assuming that the greater SUV may potentially result in greater toxicities. For the purposes of this short communication, we are strictly focusing on the SUV and do not have correlation with toxicity outcomes. To accomplish this, we compared the 3- and 6-month posttreatment fluorodeoxyglucose PET scans for 100 matched patients with oropharyngeal cancer treated definitively without surgery using either IMPT (n = 50) or IMRT (n = 50).
Our study found a significant difference in biologic dose between the high- and low-uptake regions on 3-month posttreatment scans of IMPT. However, this difference did not translate to a significant difference in PET uptake in the clinical target volume-primary at 3 and 6 months' follow-up between patients who received IMPT versus IMRT.
Studies have proposed that proton's greater relative biological effectiveness at the Bragg peak could lead to tissue inflammation. Our study did not corroborate these findings. This study's conclusion underscores the need for further investigations with ultimate correlation with clinical toxicity outcomes.
质子治疗相对于光子治疗的一个主要优势在于其能够精确地将辐射传递至靶区而无出射剂量,从而降低对周围健康组织的剂量。鉴于头颈部肿瘤与正常结构相邻,这一点至关重要。然而,质子治疗计划需要仔细考虑诸多因素,包括空气 - 组织界面、解剖学不确定性、手术伪影、体重波动、肿瘤快速反应以及设置和解剖结构的每日变化,因为这些异质性在更大程度上可能导致靶向不准确并产生不必要的热点,相较于光子辐射而言。此外,布拉格峰远端相对生物效应的升高也会增加靶区内和靶区外的热点。
本研究的目的是评估在确定性治疗后,调强质子治疗(IMPT)和调强光子治疗(IMRT)之间正电子发射断层扫描(PET)标准摄取值(SUV)的差异。此外,我们比较了接受IMPT治疗患者临床靶区 - 原发灶内PET高摄取区和低摄取区之间的生物剂量。本研究假定较高的SUV可能潜在导致更大的毒性。在本简短交流中,我们严格聚焦于SUV,且未将其与毒性结果相关联。为实现此目的,我们比较了100例经IMPT(n = 50)或IMRT(n = 50)确定性治疗且未行手术的口咽癌匹配患者治疗后3个月和6个月的氟脱氧葡萄糖PET扫描结果。
我们的研究发现,在IMPT治疗后3个月的扫描中,高摄取区和低摄取区之间的生物剂量存在显著差异。然而,在3个月和6个月随访时,接受IMPT与IMRT治疗的患者在临床靶区 - 原发灶的PET摄取方面,这种差异并未转化为显著差异。
研究表明质子在布拉格峰处具有更高的相对生物效应可能导致组织炎症。我们的研究并未证实这些发现。本研究的结论强调了进一步开展与临床毒性结果最终相关联的调查的必要性。